PMID- 32326243
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 21
TI  - Association of Proteins Modulating Immune Response and Insulin Clearance During 
      Gestation with Antenatal Complications in Patients with Gestational or Type 2 
      Diabetes Mellitus.
LID - 10.3390/cells9041032 [doi]
LID - 1032
AB  - BACKGROUND: The purpose of the study is to establish and quantitatively assess 
      protein markers and their combination in association with insulin uptake that may 
      be have value for early prospective recognition of diabetic fetopathy (DF) as a 
      complication in patients with diabetes mellitus during gestation. METHODS: 
      Proteomic surveying and accurate quantitative measurement of selected proteins 
      from plasma samples collected from the patients with gestational diabetes 
      mellitus (GDM) and type 2 diabetes mellitus (T2DM) who gave birth of either 
      healthy or affected by maternal diabetes newborns was performed using mass 
      spectrometry. RESULTS: We determined and quantitatively measured several 
      proteins, including CRP, CEACAM1, CNDP1 and Ig-family that were significantly 
      differed in patients that gave birth of newborns with signs of DF. We found that 
      patients with newborns associated with DF are characterized by significantly 
      decreased CEACAM1 (113.18 +/- 16.23 ng/mL and 81.09 +/- 10.54 ng/mL in GDM and T2DM, 
      p < 0.005) in contrast to control group (515.6 +/- 72.14 ng/mL, p < 0.005). On the 
      contrary, the concentration of CNDP1 was increased in DF-associated groups and 
      attained 49.3 +/- 5.18 ng/mL and 37.7 +/- 3.34 ng/mL (p < 0.005) in GDM and T2DM 
      groups, respectively. Among other proteins, dramatically decreased concentration 
      of IgG4 and IgA2 subclasses of immunoglobulins were noticed. CONCLUSION: The 
      combination of the measured markers may assist (AUC = 0.893 (CI 95%, 0.785-0.980) 
      in establishing the clinical finding of the developing DF especially in patients 
      with GDM who are at the highest risk of chronic insulin resistance.
FAU - Kopylov, Arthur T
AU  - Kopylov AT
AUID- ORCID: 0000-0002-7199-372X
AD  - Department of Pathology, Institute of General Pathology and Pathophysiology, 
      125315 Moscow, Russia.
AD  - Department of Proteomic Researches, Institute of Biomedical Chemistry, 119121 
      Moscow, Russia.
FAU - Kaysheva, Anna L
AU  - Kaysheva AL
AUID- ORCID: 0000-0003-4472-2016
AD  - Department of Proteomic Researches, Institute of Biomedical Chemistry, 119121 
      Moscow, Russia.
FAU - Papysheva, Olga
AU  - Papysheva O
AD  - Perinatal Center, Sergey S. Yudin 7th State Clinical Hospital, 115446 Moscow, 
      Russia.
FAU - Gribova, Iveta
AU  - Gribova I
AD  - Nikolay E. Bauman 29th State Clinical Hospital, 110020 Moscow, Russia.
AD  - "Biopharm-Test" Limited Liability Company, 121170 Moscow, Russia.
FAU - Kotaysch, Galina
AU  - Kotaysch G
AD  - Nikolay E. Bauman 29th State Clinical Hospital, 110020 Moscow, Russia.
FAU - Kharitonova, Lubov
AU  - Kharitonova L
AD  - Nikolay I. Pirogov Medical University, 117997 Moscow, Russia.
FAU - Mayatskaya, Tatiana
AU  - Mayatskaya T
AD  - Nikolay I. Pirogov Medical University, 117997 Moscow, Russia.
FAU - Krasheninnikova, Anna
AU  - Krasheninnikova A
AD  - Department of Pathology, Institute of General Pathology and Pathophysiology, 
      125315 Moscow, Russia.
FAU - Morozov, Sergey G
AU  - Morozov SG
AD  - Department of Pathology, Institute of General Pathology and Pathophysiology, 
      125315 Moscow, Russia.
AD  - Nikolay E. Bauman 29th State Clinical Hospital, 110020 Moscow, Russia.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Insulin)
RN  - 0 (Proteins)
SB  - IM
MH  - Adult
MH  - Calibration
MH  - Cluster Analysis
MH  - Diabetes Mellitus, Type 2/*immunology
MH  - Diabetes, Gestational/*immunology
MH  - Female
MH  - Gene Ontology
MH  - Humans
MH  - *Immunity
MH  - Infant, Newborn
MH  - Insulin/*metabolism
MH  - Models, Biological
MH  - Pregnancy
MH  - Proteins/*metabolism
MH  - ROC Curve
PMC - PMC7226479
OTO - NOTNLM
OT  - carnosine
OT  - diabetic fetopathy
OT  - gestational diabetes mellitus
OT  - immunoglobulins
OT  - insulin resistance
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2020/04/25 06:00
MHDA- 2021/02/23 06:00
PMCR- 2020/04/01
CRDT- 2020/04/25 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/04/01 00:00 [pmc-release]
AID - cells9041032 [pii]
AID - cells-09-01032 [pii]
AID - 10.3390/cells9041032 [doi]
PST - epublish
SO  - Cells. 2020 Apr 21;9(4):1032. doi: 10.3390/cells9041032.